Introduction. High renin-angiotensin system (RAS) activity has been associated with a high risk of severe hypoglycaemia in patients with type 1 diabetes and with cognitive deterioration during experimental hypoglycaemia in healthy subjects. The aim of this study was to describe possible differences in cerebral activity during hypoglycaemia and cognitive testing in two groups of healthy men with different basal RAS activity. Methods. Ten healthy men with high RAS activity and 10 with low activity underwent six oxygen-15-labelled water positron emission tomography scans: twice during normoglycaemia, twice during insulin-induced hypoglycaemia and twice during post-hypoglycaemia. During the scans, the subjects performed a computer-based reaction time test. Results. Occipital areas were consistently more activated in the low RAS group than in the high RAS group throughout all three conditions. During normoglycaemia, the frontal region was more activated in the low RAS group than in the high RAS group. During hypoglycaemia, the high RAS group was more activated in the pituitary gland than the low RAS group. Conclusion. Basal RAS activity influenced cerebral activity. Low RAS was associated with more pronounced cortical activation in all glycaemic conditions. High RAS was associated with pituitary activation during hypoglycaemia and post-hypoglycaemia, and this was associated with a greater growth hormone response.
Introduction
Cognitive dysfunction is a well-known consequence of hypoglycaemia. In patients with diabetes, the cognitive decline during moderate hypoglycaemia may impair self-care and thereby expose the patients to episodes with severely impaired cognition and need for assistance from other people (severe hypoglycaemia). The risk of severe hypoglycaemia is individually very variable and several studies have shown that patients with high activity of angiotensin-converting enzyme (ACE) are at much greater risk than subjects with low ACE activity. [1] [2] [3] [4] Accordingly, an experimental study of healthy subjects has shown that serum ACE activity affects the extent of cognitive deterioration during hypoglycaemia, with subjects with high serum ACE activity having significantly more cognitive deterioration than subjects with low serum ACE activity. 5 Other studies have implicated the renin-angiotensin system (RAS) in sensory modulation and cognitive functioning in normoglycaemic conditions. 6 Other parameters in the RAS apart from ACE activity have been shown to influence the risk of severe hypoglycaemia in patients with type 1 diabetes. 3 In the case of hypoglycaemia, differences in basal RAS activity may affect cerebral vulnerability to glucose depletion or modulate cerebral activation in response to cognitive tasks and thereby the request for metabolic substrates.
The aim of this study was to describe possible differences in cerebral activity during cognitive testing before, during and after a standardised hypoglycaemic condition in two groups of healthy subjects with different basal RAS activity. Changes in cerebral activity are reflected in changes in regional cerebral blood flow, and oxygen-15-labelled water (H 2 15 O) positron emission tomography (PET) provides a good estimate of cerebral flow changes because of the freely diffusible property of the tracer. 7 Methods Participants A total of 503 healthy young men from Danish educational establishments participated in a screening Differences in cortical and pituitary activity in response to hypoglycaemia and cognitive testing in healthy men with different basal activity of the renin-angiotensin system From the screening population, ten subjects with low RAS activity -defined as serum ACE and plasma angiotensinogen concentrations in the lowest quartile in the population combined with the presence of angiotensin II type 2 (AT 2 ) receptor genotype GG -and ten subjects with high RAS activity -defined as serum ACE and plasma angiotensinogen concentrations in the highest quartile in the population combined with the presence of AT 2 receptor genotype AA -were selected (table 1). These parameters have been shown to be associated with a significant risk of severe hypoglycaemia in a population of patients with type 1 diabetes. 3
Experimental set-up
Each subject provided a detailed medical history to ensure they were in good health and not taking any medication. Furthermore, any contraindication against magnetic resonance (MR) scan was an exclusion criterion. They were graded according to handedness (Edinburgh Handedness Inventory). Nineteen were strongly right-handed and one was primarily left-handed. Subjects were instructed to live and eat as normally as possible and to avoid any rigorous exercise, as well as use of alcohol and drugs, in the week preceding the experiments.
All screened participants gave their informed consent before participating in the study. The study was approved by the regional medical ethics committee (2005-2-15) and was conducted at the PET and Cyclotron Unit, Rigshospitalet, Copenhagen University Hospital, Denmark. Pooled analyses of the presented data have recently been published with evaluation of the effect of the hypoglycaemic condition on cerebral activity. 8
Experimental design
Subjects were studied after an overnight fast. Intravenous infusion lines were inserted in the left and right antecubital veins (left: injection of tracer, right: blood samples) and in the left hand (insulin infusion). Subjects remained supine in the scanner during the whole experimental session.
Following scans at normoglycaemia, insulin was given as a continuous infusion in order to induce and maintain hypoglycaemia. The target nadir plasma glucose concentration was 2.2 mmol/L. An infusion of 0.14 IE/kg/h was administered until plasma glucose was 2.5 mmol/L, whereafter the infusion was reduced to 0.07 IE/kg/h (aiming at a plasma glucose concentration of 2.2 mmol/L). Depending on bedside plasma glucose measurements, the infusion was further reduced. This approach was preferred to conventional hyperinsulinaemic hypoglycaemic clamping in order to minimise the insulin dose because insulin per se may affect cerebral metabolism and activation, 9 and to avoid the need for any exogenous glucose supply during hypoglycaemia. Blood samples were drawn twice during normoglycaemia, during hypoglycaemia and after restoration of normoglycaemia (post-hypoglycaemia). Restoration of normoglycaemia was achieved by ingestion of 250 ml apple juice.
Relative changes in regional cerebral blood flow were measured during normoglycaemia (two scans), during hypoglycaemia (two scans) and post-hypoglycaemia (two scans). During the scans, the subjects performed a cognitive test, the Danish version of the abbreviated California Computerised Assessment Package (CALCAP) test battery. 10 This test consists of four different reaction time tasks (level 1-4), with different complexity based on presentations of numbers on the computer screen. Scans were performed during level 4 and only data from this test are presented. Level 4 is a choice reaction task with reaction to presentation of two consecutive numbers in a sequence. Performance of level 4 includes the use of working memory and has previously been shown to deteriorate during moderate hypoglycaemia. 5 From the test results, the individual mean reaction time and the error rate (error rate = sum of false positive + false negative reactions) for the choice reaction test were extracted. Finally, symptoms of hypoglycaemia were rated according to the Edinburgh Hypoglycaemia Symptom Score Questionnaire. 11 Table 1 Baseline demographics and renin-angiotensin system activity. Image sequence/technique PET scans were carried out with the subjects in supine position using an Advance PET scanner (GE, Milwaukee, WI, USA) operating in 3D mode with collimating septa retracted, producing 35 image slices with a distance of 4.25 mm. The total axial field of view was 15 cm with an approximate in-plane resolution of 5 mm; each subject had an initial 2-minute scan for positioning followed by a 10-minute transmission scan for attenuation correction. Six intravenous injections of 400 MBq of H 2 15 O were given. The tracer was administered by an automatic water injection system via the left brachial vein over 30 seconds followed by 10 ml of isotonic saline for flushing. Data acquisition was triggered by total count rate build up and began about 40 seconds after injection start and lasted for about 90 seconds. There was an interval of at least 10 minutes between repeated emission scans to allow for the isotope to decay.
High
On a separate day, each subject underwent MR imaging of the brain using a 3 Tesla magnetic resonance whole body scanner (Trio, Siemens, Erlangen, Germany) to provide a MR template for the PET scans. A single three-dimensional MPRAGE (Magnetisation Prepared RApid Gradient Echo) structural imaging sequence was acquired.
Biochemical analyses
Blood samples were collected on ice, centrifuged at 5°C within 20 minutes and specimens were stored immediately after at -80°C until further analyses. Bedside plasma glucose measurements used for monitoring during the experiments were carried out by a HemoCue Analyzer (HemoCue AB, Angelholm, Sweden) every 5 minutes.
All biochemical analyses were performed blinded to the other results. Angiotensinogen was determined as the maximal quantity of angiotensin I generated during incubation of plasma in the presence of excess recombinant human renin. 12 Serum ACE activity was determined by a commercial kinetics-based assay (Sigma Diagnostics, St. Louis, MO, USA). DNA was extracted from peripheral blood leukocytes using a standard salting-out method. The ACE I/D variant and the AT 2 receptor 1675G/A polymorphism were determined by polymerase chain reaction. Blood for measurement of adrenaline was sampled into chilled tubes containing 100 µl EDTA gluthatione and heparin, centrifuged, drawn off by pipette and frozen (-80 o C) within 30 minutes. Analyses were done using HPLC with fluorimetric detection. 13 Glucose and cortisol were immediately analysed by the local laboratory. Plasma glucose concentrations were measured enzymatically (ROCHE, Switzerland). Plasma cortisol was measured by electrochemiluminescence-immunoassay (ECLIA). Serum growth hormone concentration was determined with a commercial fluoroimmunometric method (Delfia, Wallac, Finland) using two monoclonal antibodies against two separate antigenic determinants on the growth hormone molecule. Glucagon concentrations in plasma were measured with a radioimmunoassay directed against the C-terminus of the glucagon molecule (antibody code no. 4305), which mainly reflects glucagon of pancreatic origin. 14 Serum insulin was determined by using a fluoroimmunometric sandwich-assay (AutoDELFIA).
Image processing and analysis
The PET data were reconstructed with Filtered Back-Projection including attenuation to 35 128×128 pixel matrices applying an 8-mm Hanning filter and thereafter exported from the scanner's database. The voxel size of the exported images was 2.0×2.0×4.25 mm 3 .
After conversion to Analyse format, the data were analysed using Statistical Parametric Mapping (SPM5). 15 All scans of each subject were realigned, co-registered to individual MRIs and subsequently projected into a standard stereotactic threedimensional space.
The spatially normalised images of all subjects were smoothed with an isotropic Gaussian filter (full width half-maximum 14 mm).
We designed a flexible factorial model where the two factors were condition (normoglycaemia, hypoglycaemia or post-hypoglycaemia) and subjects. Comparisons of activation patterns in each condition between the two RAS groups were performed, which gave rise to six different contrasts.
Statistics (biochemical parameters)
Comparison of the three conditions (normoglycaemia, hypoglycaemia and recovery) was performed with a one-way-analysis of variance (one way ANOVA). When the assumption of normality and/ or equal variances were not fulfilled, we used the Kruskaal-Wallis test to test the between condition differences. No post hoc tests were performed.
To compare the between group (high RAS vs. low RAS) difference, an independent t-test was used when assumption of normality was fulfilled, otherwise a Mann Whitney test was applied. Normality was tested by using probability plots and Kolmogorov-Smirnov tests. A p value < 0.05 (two-sided) was considered significant. All analyses were performed with SPSS 13.0. 
Results

Hypoglycaemic stimulus, symptom scores and hormonal counter-regulation
The mean plasma glucose concentration was 2.1 mmol/L (SD 0.4) in the low RAS group and 2.2 mmol/L (SD 0.4) in the high RAS group (p=0.47) during hypoglycaemia. Hypoglycaemia was induced with a total of 0.14 U/kg (SD 0.03) regular human insulin in the high RAS group and 0.12 U/kg (SD 0.02) in the low RAS group (p=0.12). During hypoglycaemia, the serum insulin concentrations were 414 pmol/L in the low RAS group and 508 pmol/L in the high RAS group (p=0.15). The hypoglycaemic challenge was sufficient to generate adequate hormonal counter-regulatory and symptomatic responses with no between-group difference except for growth hormone, where the high RAS group had a significantly higher level in the posthypoglycaemic period (p=0.04) compared to the low RAS group (table 2) .
Cognitive function
At baseline, the high RAS group had significantly lower mean reaction times and lower error rates than the low RAS group and these differences remained unaltered throughout the experiment (table 3) . There were no differences between the RAS groups in the relative degree of the cognitive deterioration during hypoglycaemia and posthypoglycaemia.
Cerebral activation patterns
Occipital areas were consistently more activated in the low RAS group than in the high RAS group throughout all three conditions (table 4). This was Table 2 Response to hypoglycaemia according to renin-angiotensin system activity. Paper SAGE Publications 2010 Los Angeles, London, New Delhi and Singapore bilateral except during post-hypoglycaemia, where it was on the right side. During normoglycaemia, the low RAS group also activated more than the high RAS group in the frontal region and the high RAS group activated more than the low RAS group in the superior part of the left parietal lobe. During hypoglycaemia, the low RAS group activated more than the high RAS group in the right inferior temporal area and in the right dorsolateral prefrontal cortex and the high RAS group activated more than the low RAS group in the pituitary gland. During post-hypoglycaemia, the high RAS group activated more than the low RAS group in the right thalamus and the low RAS group activated more in the right lateral sulcus (table 4) .
Normoglycaemia
Discussion
In the present study, we found differences in cerebral activity in both cortical and subcortical areas between subjects with low and high RAS activity during a cognitive test. In general, the subjects with low RAS activity showed more pronounced cortical activation, whereas those with high RAS activity more in subcortical structures. There were differences regardless of which conditions were studied. We found no differences in relative cognitive deterioration during hypoglycaemia or post-hypoglycaemia between the two RAS groups. In normoglycaemia, we found that the low RAS group exhibited a pattern of higher activation than the high RAS group deep in the occipital lobe which remained throughout all three conditions. These areas are involved in analysis of visual form, motions and subject representation, 16 and indicate that differences in RAS activity influence visual processing. During normoglycaemia, the low RAS group had higher cerebral activity in the superior and inferior parts of the right frontal gyrus. These areas are involved in executive function, but also in control of eye movements. 17, 18 The high RAS group activated more than low RAS in the left parietal lobe, an area involved in visual-motor coordination. 19 Whether these differences are secondary to the inferior cognitive performance in the low RAS group or a result of the differences in basal RAS activity we can only speculate. It was unexpected that the baseline values in the cognitive test were different between the two groups. In another study evaluating the effect of differences in serum ACE activity on cognitive deterioration, it was shown that the group with high ACE deteriorated significantly during hypoglycaemia, which is in contrast to our findings. 5 In the described study, subjects were selected only on the basis of serum ACE activity and therefore are not fully comparable to the group we have studied, where other components in the RAS were included. 5
During hypoglycaemia, the pituitary gland was activated more in the high RAS group. This is interesting since this group also produced a significant higher growth hormone response. Thus, the increased pituitary activation may reflect the more pronounced counter-regulation. The observation is not explained by differences in hypoglycaemic exposure between the groups. An explanation could be the fact that the genes encoding ACE and growth hormone are neighbouring and there may be a linkage between functional genotypes between the two genes. 20 It has been previously reported that subjects with high ACE activity tend to produce a higher growth hormone response to hypoglycaemia. 5
During the post-hypoglycaemia, the high RAS group activated more in the right thalamus, indicating that RAS activity influences sensory modulation.
Our classification of RAS activity was based on measurement of systemic RAS components, each affecting the risk of developing severe hypoglycaemia in patients with type 1 diabetes. 3 It is not possible to measure intracerebral levels of RAS, but there is good correlation between ACE activity in serum and tissues due to a major genetic influence from the ACE I/D polymorphism, 21 and the AT 2 receptor polymorphism is the same as in the peripheral RAS.
The cerebral RAS is a complex system with some paradoxical effects. It has been shown that cerebral infusion of angiotensin II enhances cognition, 22, 23 but also that angiotensin II type 1 receptor blockers also enhance cognition. 24 This suggests that the RAS possesses properties where the final effect is a result of the balanced effect of the stimulation and inhibition of the receptors.
The function of the cerebral RAS is not fully known, but current knowledge suggests that genetic heterogeneity may influence the brain's response during pathological conditions like hypoxia or hypoglycaemia. 24 In the present study, we have now established that during a state of substrate depletion (hypoglycaemia), using a cognitive reaction time test, RAS activity affects cerebral activity responses. In the future, it would be of major interest to evaluate the effect of blockers of the intracerebral RAS on cerebral activity and cognition. 
